Impact of IDDM2 on disease pathogenesis and progression in children with newly diagnosed type 1 diabetes: reduced insulin antibody titres and preserved beta cell function

Nielsen, L.; Mortensen, H.; Chiarelli, F.; Holl, R.; Swift, P.; Beaufort, C.; Pociot, F.; Hougaard, P.; Gammeltoft, S.; Knip, M.; Hansen, L.
January 2006
Diabetologia;Jan2006, Vol. 49 Issue 1, p71
Academic Journal
Aims/hypothesis: The insulin-dependent diabetes mellitus 2 gene (IDDM2) is a type 1 diabetes susceptibility locus contributed to by the variable number of tandem repeats (VNTR) upstream of the insulin gene (INS). We investigated the association between INS VNTR class III alleles (-23HphIA/T) and both insulin antibody presentation and residual beta cell function during the first year after diagnosis in 257 children with type 1 diabetes. Materials and methods: To estimate C-peptide levels and autoantibody presentation, patients underwent a meal-stimulated C-peptide test 1, 6, and 12 months after diagnosis. The insulin -23HphIA/T variant was used as a marker of class III alleles and genotyped by PCR-RFLP. Results: The insulin antibody titres at 1 and 6 months were significantly lower in the class III/III and class I/III genotype groups than in the class I/I genotype group (p = 0.01). Class III alleles were also associated with residual beta cell function 12 months after diagnosis and independently of age, sex, BMI, insulin antibody titres, and HLA-risk genotype group (p = 0.03). The C-peptide level was twice as high among class III/III genotypes as in class I/I and class I/III genotypes (319 vs 131 and 166 pmol/l, p=0.01). Furthermore, the class III/III genotype had a 1.1% reduction in HbA1c after adjustment for insulin dose (p = 0.04). Conclusions/interpretation: These findings suggest a direct connection in vivo between INS VNTR class III alleles, a decreased humoral immune response to insulin, and preservation of beta cell function in recent-onset type 1 diabetes.


Related Articles

  • Correlation of insulin resistance, beta cell function and insulin sensitivity with serum sFas and sFasL in newly diagnosed type 2 diabetes. Kumar, Hemant; Mishra, Manish; Bajpai, Surabhi; Pokhria, Deepa; Arya, Awadhesh; Singh, Rakesh; Tripathi, Kamlakar // Acta Diabetologica;Aug2013, Vol. 50 Issue 4, p511 

    Pancreatic beta cell dysfunction and reduced insulin sensitivity are fundamental factors associated with glucotoxicity, lipotoxicity and oxidative stress in type 2 diabetic patients (T2DM). Diabetic milieu can induce apoptosis in several types of cells. The aim of present study was to compare...

  • Binding Orientations and Lipid Interactions of Human Amylin at Zwitterionic and Anionic Lipid Bilayers. Qian, Zhenyu; Jia, Yan; Wei, Guanghong // Journal of Diabetes Research;11/16/2015, p1 

    Increasing evidence suggests that the interaction of human islet amyloid polypeptide (hIAPP) with lipids may facilitate hIAPP aggregation and cause the death of pancreatic islet β-cells. However, the detailed hIAPP-membrane interactions and the influences of lipid compositions are unclear. In...

  • The Role of Helicobacter pylori Seropositivity in Insulin Sensitivity, Beta Cell Function, and Abnormal Glucose Tolerance. Malamug, Lou Rose; Karnchanasorn, Rudruidee; Samoa, Raynald; Chiu, Ken C. // Scientifica;2014, p1 

    Infection, for example, Helicobacter pylori (H. pylori), has been thought to play a role in the pathogenesis of type 2 diabetesmellitus (T2DM). Our aim was to determine the role of H. pylori infection in glucose metabolism in an American cohort. We examined data from 4,136 non-Hispanic white...

  • Selenoprotein P as a significant regulator of pancreatic β cell function. Saito, Yoshiro // Journal of Biochemistry;Feb2020, Vol. 167 Issue 2, p119 

    Selenoprotein P (SeP; encoded by SELENOP) is selenium (Se)-rich plasma protein that is mainly produced in the liver. SeP functions as a Se-transport protein to deliver Se from the liver to other tissues, such as the brain and testis. The protein plays a pivotal role in Se metabolism and...

  • Insulin secretion: movement at all levels. Henquin, Jean-Claude; Boitard, Christian; Efendic, Suad; Ferrannini, Ele; Steiner, Donald F.; Cerasi, Erol // Diabetes;Feb2002 Supplement, Vol. 51, pS1 

    Editorial. Examines the effects of insulin resistance on type two diabetes. Increase of cytosolic beta-cells; Decrease of hyperglycemia; Release of the glucose metabolism.

  • A model to explore the interaction between muscle insulin resistance and beta-cell dysfunction in the development of type 2 diabetes. Mauvais-Jarvis, Franck; Virkamaki, Antti; Michael, M. Dodson; Winnay, Jonathon N.; Zisman, Ariel; Kulkarni, Rohit N.; Kahn, C. Ronald; Mauvais-Jarvis, F; Virkamaki, A; Michael, M D; Winnay, J N; Zisman, A; Kulkarni, R N; Kahn, C R // Diabetes;Dec2000, Vol. 49 Issue 12, p2126 

    Type 2 diabetes is a polygenic disease characterized by defects in both insulin secretion and insulin action. We have previously reported that isolated insulin resistance in muscle by a tissue-specific insulin receptor knockout (MIRKO mouse) is not sufficient to alter glucose homeostasis,...

  • Accurate Assessment of β-Cells Function. Bergman, Richard N.; Ader, Marilyn; Huecking, Katrin; Van Citters, Gregg // Diabetes;Feb2002 Supplement, Vol. 51, pS212 

    Only in the last decade did modeling studies predict, and knockout experiments confirm, that type 2 diabetes is a “2-hit” disease in which insulin resistance is necessarily accompanied by β-cell defect(s) preventing the compensatory upregulation of insulin secretion. This...

  • Contributions of Insulin-Resistance and Insulin-Secretory Defects to the Pathogenesis of Type 2 Diabetes Mellitus. Gerich, John E. // Mayo Clinic Proceedings;Apr2003, Vol. 78 Issue 4, p447 

    Examines the role of insulin resistance and insulin-secretory defects in the pathogenesis of type-2 diabetes mellitus. Genetic factors involved in the alteration of insulin sensitivity and impairment of beta-cell function; Importance of optimal glycemic control in the management of diabetes;...

  • Insulin-dependent actions of pioglitazone in newly diagnosed, drug naïve patients with type 2 diabetes. Takuya Fukushima // Endocrine (1355008X);Jun2009, Vol. 35 Issue 3, p333 

    Abstract  The aim of this study was to study the effects of pioglitazone on several diabetic parameters with subjects possessing distinct levels of insulin. Treatment naive patients with type 2 diabetes received 15–30 mg/day pioglitazone monotherapy. At...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics